The U.S. Food and Drug Administration has approved Roseland, N.J.-based Intervet’s new animal drug application for the veterinary prescription use of Posatex (orbifloxacin, mometasone furoate monohydrate, and posaconazole) Otic Suspension for the treatment of otitis externa in dogs.
Effective as of April 1, 2010, this drug is for treatment of otitis externa associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (coagulase-positive staphylococci, Pseudomonas aeruginosa, and Enterococcus faecalis).
The conditions of use in dogs include specific dosage amounts according to weight. For dogs less than 30 pounds, the required dosage is four drops once daily into the ear canal. For dogs weighing more than 30 pounds, the dosage should be increased to eight drops into the ear canal, according to the FDA.
Federal law restricts this drug solely for use by or on the order of a licensed veterinarian.